At Nanostics our focus is on the development of novel and non-invasive diagnostic tests to eliminate invasive testing and provide clarity to healthcare decisions.


Nanostics Inc. is a medical device and biotechnology company.

Our Mission Statement: Providing clarity to people about their health by enabling better diagnosis and improving health care decisions through artificial intelligence and nanoparticle detection.


Our core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose disease from a simple blood test.This technology is applicable to a wide range of diseases, including prostate, brain, pancreatic, and blood cancers as well as cardiovascular and neuro-degenerative diseases.

ClarityDX Prostate, our lead product currently in clinical trials, is designed to be a highly accurate test to predict clinically significant prostate cancer.This technology is positioned to emerge as the leading diagnostic tool, bringing clarity to healthcare decisions for prostate cancer.Please note: this product is in development and so currently has not received regulatory approval or clearance in any markets.

Our Leadership Team


-Management-

John D. Lewis | PhD, Founder, Board Chair and Chief Executive Officer

Dr. Lewis is the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta, Edmonton, Alberta. In addition to his academic work, Dr. Lewis is the co-founder of Innovascreen Inc., a successful preclinical CRO in operation since 2005, and the founder and CEO of ENTOS Pharmaceuticals Inc., a Drug Delivery Company incorporated in 2007. His research involves cancer diagnostics, non-invasive molecular imaging and targeting of angiogenesis and metastasis using multivalent nanoparticles. He trained at The Scripps Research Institute in La Jolla, CA, developing targeted molecular imaging technologies. Dr. Lewis earned a Ph.D. in biochemistry from the University of Victoria.

Adrian Fairey | MD, FRCS(C), MSc, Medical Officer

Dr. Fairey is an active uro-oncology surgeon and clinical trials team leader at the Northern Alberta Urology Centre (NAUC) in Edmonton, Alberta who specializes in surgical procedures for bladder, prostate, and kidney cancers. He is also the Director of the NAUC Research Institute and Co-Principal Investigator in the Alberta Prostate Cancer Research Initiative (APCaRI). Dr. Fairey is involved in urologic oncology at the national level as a member of the Canadian Bladder Cancer Network, Canadian Upper Tract Collaboration, Bladder Cancer Canada, and the global Prostate Cancer Outcomes to compare and reduce variation program. He is a reviewer for several peer-reviewed cancer and urology journals. Dr. Fairey earned his Master’s degree from the University of Alberta in 2001 and his MD, FRCS (C) from the University of Alberta in 2006.

Eric Hyndman | MD, FRCS(C), PhD, Medical Officer

Dr. Eric Hyndman is an active uro-oncology surgeon at the Southern Alberta Institute of Urology (SAIU) in Calgary, Alberta and clinical assistant professor of urology who subspecializes in minimally invasive, robotic and open surgical treatment of urologic malignancies. He earned both his PhD in medical sciences and his MD at the University of Calgary. Dr. Hyndman completed a residency in Urology at the University of Alberta in Edmonton and continued his studies with a fellowship at Johns Hopkins in Urologic Oncology. Dr. Hyndman also has an active and expanding research program investigating prostate and bladder cancers. In particular, he leads the prostate cancer active surveillance program in Calgary and within this population is trying to determine what causes progression to an aggressive disease.

Catalina Vasquez | MSc., CIM, Chief Operating Officer

Ms. Vasquez has over 9 years of management experience. Ms. Vasquez is the former Program Director for the Alberta Prostate Cancer Research Initiative (APCaRI), where she coordinated the translational goals of the team. APCaRI’s overall goal is to develop new diagnostic tests for prostate cancer, to discover novel biomarkers for aggressive prostate cancer, and to conduct clinical trials to establish the value of new diagnostics in the clinic. She was also the lead at the Prostate Cancer Registry and Biorepository in Edmonton, Alberta. Prior to coming to Alberta, she served as Project Manager for Investigator Initiated Trials with the Lawson Health Research Institute at the London Health Sciences Centre, and as Laboratory Manager in Dr. John Lewis' laboratory at Western University. Ms. Vasquez earned her MSc. in Medical Biophysics at Western University in 2011.

Desmond Pink | PhD, Chief Scientific Officer

Dr. Pink is the lead researcher in the development and validation of the Nanostics diagnostics platform and has considerable expertise in scientific team management, as well as biochemistry, protein synthesis and experimental therapeutics. Dr. Pink earned his Ph.D. in Nutrition and Metabolism at the University of Alberta in Edmonton, Alberta. Prior to joining Nanostics, he was the Senior Research Scientist and Project Manager at Entos Pharmaceuticals and Project Manager with Innovascreen Inc. Dr. Pink also investigated the cell signaling machinery of intestinal cancer cells as a Postdoctoral Fellow at Dalhousie University.

Robert Paproski | PhD, Chief Technology Officer

Dr. Paproski has been the lead technology researcher in the development and validation of the machine learning platform/fingerprint at Nanostics. Since earning his B.Sc. in Pharmacology and Ph.D. in Oncology at the University of Alberta, Dr. Robert Paproski has developed a broad range of skills over multiple disciplines centered on diagnostics using a variety of imaging technologies. His experience also includes data analysis using MATLAB, R, and Python to predict clinical outcomes using state-of-the-art algorithms such as XGBoost and deep artificial neural networks.

Colin Coros | PhD, MBA, ICD.D, Chief Commercialization Officer

Dr. Coros is an experienced executive specializing in life sciences and health technologies. As the former CEO of the Delta Genomics Centre, Dr. Coros built a national diagnostics company for the livestock industry. He is also the co-founder of Helios Genomics, a metagenomics company specializing in the Energy sector. Colin earned a PhD in Biochemistry from the University of Western Ontario, an MBA from the Edward School of Business at the University of Saskatchewan in Saskatoon, Saskatchewan, and completed Postdoctoral Fellowships at the Wadsworth Centre in Albany, New York and the University of Calgary in Calgary, Alberta.

-Board of Directors-

John D. Lewis | PhD, Founder, Board Chair and Chief Executive Officer

Dr. Lewis is the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta, Edmonton, Alberta. In addition to his academic work, Dr. Lewis is the co-founder of Innovascreen Inc., a successful preclinical CRO in operation since 2005, and the founder and CEO of ENTOS Pharmaceuticals Inc., a Drug Delivery Company incorporated in 2007. His research involves cancer diagnostics, non-invasive molecular imaging and targeting of angiogenesis and metastasis using multivalent nanoparticles. He trained at The Scripps Research Institute in La Jolla, CA, developing targeted molecular imaging technologies. Dr. Lewis earned a Ph.D. in biochemistry from the University of Victoria.

Dale Klein | President and CEO of Canada ICI Capital Corporation

Mr. Klein is the President and CEO of Canada ICI Capital Corporation, an established commercial mortgage brokerage firm specializing in full service brokerage operations. As the original founder of Canada ICI in 1993, Mr. Klein has grown the company to now have offices in Edmonton, Calgary, Winnipeg and Toronto, with annual origination volumes in excess of $2.5 billion. He has been actively involved in commercial real estate finance since 1986. With his extensive knowledge of both the debt and equity markets, he has personally arranged in excess of $8.0 billion of capital over his career. Mr. Klein is also the founder and a serving Board Members of Sector Mortgage Management Inc., a federally chartered mortgage investment corporation with assets in excess of $200 million. In addition, Mr. Klein is a member of the Real Estate Council of Alberta, a past Chair of the Sturgeon Industrial Heartland Advisory Committee and currently serves as Board Member and Audit Committee Chair of the Edmonton International Airport Authority as a Sturgeon Country Representative. He is a resident of Sturgeon County, AB.

Armen G. Aprikian | M.D., F.R.C.S.(C), Richard Tomlinson Professor in Prostate Cancer, McGill University

Dr. Armen Aprikian graduated from the University of Sherbrooke Medical School in Quebec in 1985 and completed his urology residency training at McGill University in 1990. He then pursued a 3-year research and clinical fellowship in urologic oncology at Memorial Sloan Kettering Cancer Centre in New York City. In 2004 he became the Head of the Division of Urology at McGill University and the Chief of Urology at the McGill University Health Centre (MUHC). In 2007 he became Full Professor of Surgery and Oncology and in 2009 he was appointed the Medical Director of the MUHC Cancer Care Mission and Chief of the Department of Oncology. Finally, in 2010 he was appointed the McGill University Richard Tomlinson Professor in Prostate Cancer. Dr. Aprikian has been awarded the American Society of Clinical Oncology Young Investigator Award, the American Urologic Association Practicing Urologist Award, the Canadian Urology Association Scholarship, the McGill University William Dawson Scholar Career Award and the Quebec FRSQ Senior Clinician Scientist Award. He has obtained independent peer-reviewed grants from several organizations including the US Department of Defense and the National Cancer Institute. He is actively involved in a leadership role in provincial guidelines in prostate and bladder cancer surgery outcomes and has published over 230 peer-reviewed original scientific papers. Finally, in 2020 he will become the President of the Canadian Urology Association.

Reg Joseph | CEO, Health City.

Reg currently serves as the CEO of Health City. He brings a wealth of expertise in both the biomedical sciences as well as business development. Most recently, Reg Joseph served as the Vice President of the Health portfolio at Alberta Innovates. In this role, he led the provincial strategy for health innovation and drove industry and non-profit collaborations with the province. Reg has 20 years’ experience spanning the biotechnology and high technology sectors, that included serving as the CEO of a local University of Alberta start-up company, Metabolomic Technologies Inc. The company received the Frost & Sullivan Technology Leadership Award in 2014 and was declared the University of Alberta’s “Start-up of the Year” in 2013. Reg’s additional experience includes serving as an equity research analyst with Boston-based Leerink Swann & Co., where he covered the life science tools sector. He also spent four years at US-based Invitrogen Corp. (now Thermo Fisher) in a variety of roles including licensing, product development, acquisitions and integration. Reg has served in a variety of C-level and board positions with local medical technology-based start-ups. He currently serves on the Board of BioTalent Canada as Treasurer and Chair of Finance Committee. Reg also sits on BioAlberta’s policy committee and serves as President of the Board for the Seniors Association of Greater Edmonton (SAGE). He has a B.Sc. in Physiology and an MBA in Finance.

B. Melina Cimler | Ph.D. , CEO and Founder, PandiaDx LLC.

Melina Cimler is the CEO and Founder of PandiaDx LLC. She has over 28 years of experience in the life science and FDA-regulated diagnostic industry, leading regulatory, quality systems, clinical affairs, research, and product development organizations, with a focus on precision medicine. Dr. Cimler served as Senior Vice President of Regulatory & Quality at Adaptive Biotechnologies until April 2018. She was previously Head of Global Quality and Vice President of Quality, Regulatory, Clinical, and Government Affairs at Illumina Inc. She defined and executed on the regulatory strategy resulting in the first next generation sequencing platform receiving FDA marketing authorization (Illumina’s MiSeqDx). Previously, she held leadership positions in quality, regulatory and government affairs as Senior Vice President at Beckman Coulter Inc. She also served in senior quality, clinical and regulatory roles at Abbott Molecular, Gen-Probe Inc., and C.R. Bard, and as head of Product Development at Epitope, Inc. (now OraSure Technologies). Dr. Cimler earned a Ph.D. in Pharmacology from the University of Washington.